Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: Therapeutic potential for endometrial cancer

Endocrinology

Volumn 154, Issue 11, 2013, Pages 4030-4045

  Pavlides, Savvas C ^a   Huang, Kuang Tzu ^a   Reid, Dylan A ^a   Wu, Lily ^a   Blank, Stephanie V ^a   Mittal, Khushbakhat ^a   Guo, Lankai ^b   Rothenberg, Eli ^a   Rueda, Bo ^b,c   Cardozo, Timothy ^a   Gold, Leslie I ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; ESTRADIOL; LIGASE INHIBITOR; PROTEIN P27; RETINOBLASTOMA PROTEIN; SKP2E3 LIGASE INHIBITOR; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE E3 CKS1; UBIQUITIN PROTEIN LIGASE E3 SCF SKP2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CARCINOMA CELL; CELL CYCLE PROGRESSION; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DEGRADATION; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; EPITHELIUM CELL; FEMALE; FLUORESCENCE MICROSCOPY; G1 PHASE CELL CYCLE CHECKPOINT; GROWTH STIMULATION; HALF LIFE TIME; IC 50; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CDC2-CDC28 KINASES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CULLIN PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MULTIPROTEIN COMPLEXES; PROTEIN TRANSPORT; RNA INTERFERENCE; S-PHASE KINASE-ASSOCIATED PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84886546357     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1757     Document Type: Article

References (65)

1. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008;8(4): 253-267.
2. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12): 1501-1512.
3. Besson A, Hwang HC, Cicero S, et al. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev. 2007;21(14): 1731-1746.
4. Wander SA, Zhao D, Slingerland JM. p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res. 2011;17(1): 12-18.
5. Serres MP, Zlotek-Zlotkiewicz E, Concha C, et al. Cytoplasmic p27 is oncogenic and cooperates with Ras both in vivo and in vitro. Oncogene. 2011;30(25): 2846-2858.
6. Denicourt C, Saenz CC, Datnow B, Cui XS, Dowdy SF. Relocalized p27Kip1 tumor suppressor functions as a cytoplasmic metastatic oncogene in melanoma. Cancer Res. 2007;67(19): 9238-9243.
7. Larrea MD, Wander SA, Slingerland JM. p27 as Jekyll and Hyde: regulation of cell cycle and cell motility. Cell Cycle. 2009;8(21): 3455-3461.
8. Chu I, Sun J, Arnaout A, et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell. 2007;128(2): 281-294.
9. Kelly-Spratt KS, Philipp-Staheli J, Gurley KE, Hoon-Kim K, Knoblaugh S, Kemp CJ. Inhibition of PI-3K restores nuclear p27Kip1 expression in a mouse model of Kras-driven lung cancer. Oncogene. 2009;28(41): 3652-3662.
10. Chen Y, Alvarez EA, Azzam D, et al. Combined Src andERblockade impairs human breast cancer proliferation in vitro and in vivo. Breast Cancer Res Treat. 2011;128(1): 69-78.
11. Lecanda J, Parekh TV, Gama P, et al. Transforming growth factor-β, estrogen, and progesterone converge on the regulation of p27Kip1 in the normal and malignant endometrium. Cancer Res. 2007;67(3): 1007-1018.
12. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol. 2003;13(1): 41-47.
13. Huang KT, Pavlides SC, Lecanda J, Blank SV, Mittal KR, Gold LI. Estrogen and progesterone regulate p27kip1 levels via the ubiquitinproteasome system: pathogenic and therapeutic implications for endometrial cancer. PLoS One. 2012;7(9):e46072.
14. Ishida N, Hara T, Kamura T, Yoshida M, Nakayama K, Nakayama KI. Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem. 2002;277(17): 14355-14358.
15. Shin I, Rotty J, Wu FY, Arteaga CL. Phosphorylation of p27Kip1 at Thr-157 interferes with its association with importin α during G1 and prevents nuclear re-entry. J Biol Chem. 2005;280(7): 6055-6063.
16. Wen S, So Y, Singh K, et al. Promotion of cytoplasmic mislocalization of p27 by Helicobacter pylori in gastric cancer. Oncogene. 2012;31(14): 1771-1780.
17. Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med. 2002;8(10): 1153-1160.
18. Kruck S, Merseburger AS, Hennenlotter J, et al. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma. BJU Int. 109(10): 1565-1570.
19. Duncan TJ, Al-Attar A, Rolland P, Harper S, Spendlove I, Durrant LG. Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer. Int J Gynecol Pathol. 2010;29(1):8-18.
20. Hidaka T, Hama S, Shrestha P, et al. The combination of low cytoplasmic and high nuclear expression of p27 predicts a better prognosis in high-grade astrocytoma. Anticancer Res. 2009;29(2): 597-603.
21. Lecanda J, Ganapathy V, D'Aquino-Ardalan C, et al.TGFβ prevents proteasomal degradation of the cyclin-dependent kinase inhibitor p27kip1 for cell cycle arrest. Cell Cycle. 2009;8(5): 742-756.
22. Kane RC, Farrell AT, Sridhara R, Pazdur R. United States food and drug administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res. 2006;12(10): 2955-2960.
23. Diefenbach CS, O'Connor OA. Mantle cell lymphoma in relapse: the role of emerging new drugs. Curr Opin Oncol. 2010;22(5): 419-423.
24. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008;14(6): 1649-1657.
25. Kitagawa K, Kotake Y, Kitagawa M. Ubiquitin-mediated control of oncogene and tumor suppressor gene products. Cancer Sci. 2009; 100(8): 1374-1381.
26. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67: 425-479.
27. Hao B, Zheng N, Schulman BA, et al. Structural basis of the Cks1- dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol Cell. 2005;20(1):9-19.
28. Cardozo T, Abagyan R. Druggability of SCF ubiquitin ligase-protein interfaces. Methods Enzymol. 2005;399: 634-653.
29. Cardozo T, Pagano M. Wrenches in the works: drug discovery targeting the SCF ubiquitin ligase and APC/C complexes. BMC Biochem. 2007;8(suppl 1):S9.
30. WuL, Grigoryan AV, Li Y, Hao B, Pagano M, Cardozo TJ. Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem Biol. 2012;19(12): 1515-1524.
31. Kamata Y, Watanabe J, Nishimura Y, et al. High expression of skp2 correlates with poor prognosis in endometrial endometrioid adenocarcinoma. J Cancer Res Clin Oncol. 2005;131(9): 591-596.
32. Davidovich S, Ben-Izhak O, Shapira M, Futerman B, Hershko DD. Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer. Breast Cancer Res. 2008;10(4):R63.
33. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer. Nat Rev Cancer. 2008;8(6): 438-449.
34. Lin HK, Chen Z, Wang G, et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature. 2010; 464(7287): 374-379.
35. Assoian RK, Yung Y. A reciprocal relationship between Rb and Skp2: implications for restriction point control, signal transduction to the cell cycle and cancer. Cell Cycle. 2008;7(1):24-27.
36. Silverberg SG. Hyperplasia and carcinoma of the endometrium. Semin Diagn Pathol. 1988;5(2): 135-153.
37. Malkusch S, Muranyi W, Müller B, Kräusslich HG, Heilemann M. Single-molecule coordinate-based analysis of the morphology of HIV-1 assembly sites with near-molecular spatial resolution. Histochem Cell Biol. 2013;139(1): 173-179.
38. van de Linde S, Löschberger A, Klein T, et al. Direct stochastic optical reconstruction microscopy with standard fluorescent probes. Nat Protoc. 2011;6(7): 991-1009.
39. Yamaguchi S, Reid DA, Rothenberg E, Darwin AJ. Changes in Psp protein binding partners, localization and behaviour upon activation of the Yersinia enterocolitica phage shock protein response. Mol Microbiol. 2013;87(3): 656-671.
40. Hong M, Bao L, Kefaloyianni E, et al. Heterogeneity of ATP-sensitive K+ channels in cardiac myocytes: enrichment at the intercalated disk. J Biol Chem. 2012;287(49): 41258-41267.
41. Chkourko HS, Guerrero-Serna G, Lin X, et al. Remodeling of mechanical junctions and of microtubule-associated proteins accompany cardiac connexin43 lateralization. Heart Rhythm. 2012;9(7): 1133-1140.e1136.
42. Tokunaga M, Imamoto N, Sakata-Sogawa K. Highly inclined thin illumination enables clear single-molecule imaging in cells. Nat Methods. 2008;5(2): 159-161.
43. Lee SH, Baday M, Tjioe M, et al. Using fixed fiduciary markers for stage drift correction. Opt Express. 2012;20(11): 12177-12183.
44. Baday M, Cravens A, Hastie A, et al. Multicolor super-resolution DNA imaging for genetic analysis. Nano Lett. 2012;12(7): 3861-3866.
45. Rothenberg E, Ha T. Single-molecule FRET analysis of helicase functions. Methods Mol Biol. 2010;587: 29-43.
46. Henriques R, Lelek M, Fornasiero EF, Valtorta F, Zimmer C, Mhlanga MM. QuickPALM: 3D real-time photoactivation nanoscopy image processing in ImageJ. Nat Methods. 2010;7(5): 339-340.
47. Muggia F, Gold LI, Curtin J. Future Directions: New Targets. Totowa, NJ: Humana Press, Inc; 2009.
48. Bashir T, Pagan JK, Busino L, Pagano M. Phosphorylation of Ser72 is dispensable for Skp2 assembly into an active SCF ubiquitin ligase and its subcellular localization. Cell Cycle. 2010;9(5): 971-974.
49. Boutonnet C, Tanguay PL, Julien C, Rodier G, Coulombe P, Meloche S. Phosphorylation of Ser72 does not regulate the ubiquitin ligase activity and subcellular localization of Skp2. Cell Cycle. 2010; 9(5): 975-979.
50. Gao D, Inuzuka H, Tseng A, Chin RY, Toker A, Wei W. Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol. 2009; 11(4): 397-408.
51. Lin HK, Wang G, Chen Z, et al. Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol. 2009;11(4): 420-432.
52. van de Linde S, Endesfelder U, Mukherjee A, et al. Multicolor photoswitching microscopy for subdiffraction-resolution fluorescence imaging. Photochem Photobiol Sci. 2009;8(4): 465-469.
53. Cunha GR, Cooke PS, Kurita T. Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol. 2004;67(5): 417-434.
54. Kurita T, Young P, Brody JR, Lydon JP, O'Malley BW, Cunha GR. Stromal progesterone receptors mediate the inhibitory effects of progesterone on estrogen-induced uterine epithelial cell deoxyribonucleic acid synthesis. Endocrinology. 1998;139(11): 4708-4713.
55. Ellenson LH, Wu TC. Focus on endometrial and cervical cancer. Cancer Cell. 2004;5(6): 533-538.
56. Lacey JV Jr, Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas. 2009;63(1): 39-44.
57. Kotoshiba S, Kamura T, Hara T, Ishida N, Nakayama KI. Molecular dissection of the interaction between p27 and KPC, the ubiquitin ligase that regulates proteolysis of p27 in G1 phase. J Biol Chem. 2005.
58. Szafran AT, Hartig S, Sun H, et al. Androgen receptor mutations associated with androgen insensitivity syndrome: a high content analysis approach leading to personalized medicine. PLoS One. 2009;4(12):e8179.
59. Szafran AT, Szwarc M, Marcelli M, Mancini MA. Androgen receptor functional analyses by high throughput imaging: determination of ligand, cell cycle, and mutation-specific effects. PLoS One. 2008; 3(11):e3605.
60. Ashcroft FJ, Newberg JY, Jones ED, Mikic I, Mancini MA. High content imaging-based assay to classify estrogen receptor-α ligands based on defined mechanistic outcomes. Gene. 2011; 477(1-2): 42-52.
61. Rico-Bautista E, Yang CC, Lu L, Roth GP, Wolf DA. Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells. BMC Biol. 2010;8:153.
62. Chan CH, Morrow JK, Li CF, et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 2013;154(3): 556-568.
63. Ungermannova D, Lee J, Zhang G, DallmannHG,McHenryCS, Liu X. High-throughput screening AlphaScreen assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1. J Biomol Screen. 2013;18(8): 910-920.
64. Rico-Bautista E, Wolf DA. Skipping cancer: small molecule inhibitors of SKP2-mediated p27 degradation. Chem Biol. 2012;19(12): 1497-1498.
65. Gstaiger M, Jordan R, Lim M, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA. 2001;98(9): 5043-5048.